Literature DB >> 21413648

Use of spironolactone in dermatology.

Deepani Rathnayake1, Rodney Sinclair.   

Abstract

Spironolactone has been used as a potassium-sparing diuretic for more than 30 years. It is a synthetic 17-lactone steroid and primarily acts as an aldosterone antagonist. Since the accidental discovery of its antiandrogenic effects, it has been used in the treatment of many dermatologic conditions in which androgen plays a role in the pathogenesis. Antiandrogenic effects of spironolactone are exerted by reducing testosterone production and inhibiting its action on the target tissues. Spironolactone is used as a primary medical treatment for hirsutism and female pattern hair loss. Continuous treatment is required to sustain the effect. It is an effective alternative treatment for acne in women. It has the benefit of a long-term safety profile. Spironolactone should not be used in pregnancy due to its teratogenic effects and is not used in men due to the risk of feminization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21413648

Source DB:  PubMed          Journal:  Skinmed        ISSN: 1540-9740


  10 in total

1.  Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience.

Authors:  Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

2.  Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study.

Authors:  Kerri Beckmann; Hans Garmo; Bertil Lindahl; Lars Holmberg; Pär Stattin; Jan Adolfsson; J Kennedy Cruickshank; Mieke Van Hemelrijck
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-03-02       Impact factor: 5.554

3.  A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair.

Authors:  Or David Shahar; Alkmini Kalousi; Lital Eini; Benoit Fisher; Amelie Weiss; Jonatan Darr; Olga Mazina; Shay Bramson; Martin Kupiec; Amir Eden; Eran Meshorer; Alexander V Mazin; Laurent Brino; Michal Goldberg; Evi Soutoglou
Journal:  Nucleic Acids Res       Date:  2014-03-25       Impact factor: 16.971

Review 4.  Adult-onset acne: prevalence, impact, and management challenges.

Authors:  Marco A Rocha; Ediléia Bagatin
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-02-01

5.  Management of severe acne during pregnancy: A case report and review of the literature.

Authors:  S Z Awan; J Lu
Journal:  Int J Womens Dermatol       Date:  2017-07-13

6.  Uterine transplantation in transgender women.

Authors:  B P Jones; N J Williams; S Saso; M-Y Thum; I Quiroga; J Yazbek; S Wilkinson; S Ghaem-Maghami; P Thomas; J R Smith
Journal:  BJOG       Date:  2018-09-20       Impact factor: 6.531

7.  Topical Treatment of Human Skin and Cultured Keratinocytes with High-Dose Spironolactone Reduces XPB Expression and Induces Toxicity.

Authors:  M Alexandra Carpenter; Michael G Kemp
Journal:  JID Innov       Date:  2021-05-06

Review 8.  Female pattern alopecia: current perspectives.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Int J Womens Health       Date:  2013-08-29

Review 9.  Spironolactone and XPB: An Old Drug with a New Molecular Target.

Authors:  Ryan D Gabbard; Robert R Hoopes; Michael G Kemp
Journal:  Biomolecules       Date:  2020-05-13

10.  Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies.

Authors:  Ayman Salama; Mohamed Badran; Mohammed Elmowafy; Ghareb M Soliman
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.